GWPH stock data

(
)

Calendar

8 May 19
18 Jun 19

News

Company financial data Financial data

Quarter (USD) Mar 19 Dec 18 Sep 18 Jun 18
Revenue 39.25M 6.65M 2.42M 3.28M
Net income -50.06M -71.91M -79.88M -84.01M
Diluted EPS -0.14 -0.2 -0.23 -0.25
Net profit margin -128% -1081% -3301% -2558%
Operating income -51.34M -73.34M -80.61M -81.41M
Net change in cash -69.83M 236.58M
Cash on hand 521.67M 591.5M 354.91M
Cost of revenue 5.13M 1.83M
Annual (USD) Sep 18 Sep 17 Sep 16
Revenue 12.74M 8.63M 12.73M
Net income -295.17M -170.46M -91.7M
Diluted EPS -0.88 -0.56 -0.34
Net profit margin -2317% -1975% -720%
Operating income -288.8M -166.16M -128.65M
Net change in cash 32.76M
Cash on hand 354.91M 322.15M
Cost of revenue 5.99M 4.52M 3.82M

Financial data from company earnings reports

Financial report summary

?
Management Discussion
  • Our product net sales consist of sales of Epidiolex, which we launched in the United States in November of 2018 and also sell through certain early access programs outside of the United States, and sales of Sativex outside of the United States pursuant to license agreements with commercial partners.
  • Product net sales for the three months ended March 31, 2019 consist of $33.5 million in net sales of Epidiolex in the United States, $1.2 million of Epidiolex sales under early access programs outside of the United States, and $4.3 million in net sales of Sativex.
  • The $36.2 million increase in product net sales to $39.0 million for the three months ended March 31, 2019 compared to $2.8 million for the three months ended March 31, 2018 was primarily due to the recent launch of Epidiolex in the United States.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg